Mediolanum Acquires Phase II-Ready Cancer Vaccine From Italy’s Genovax
This article was originally published in The Pink Sheet Daily
Executive Summary
Italian life sciences seed capital firm Eporgen Venture has used a network of wealthy individuals in Italy to fund a group of new biotech companies, and has entered into its first transaction, selling Genovax’s potential cancer vaccine to Italian pharmaceutical company Mediolanum.
You may also be interested in...
Deals Of The Week: Baxter/Gambro, Optimer/AstraZeneca, Ironwood/Protagonist
Three rapid-fire clinical setbacks scuttled a planned merger between BioCryst and Presidio that would have created a new competitor in the hepatitis C space. Now, BioCryst is retrenching with a staff cut and narrower R&D focus.
Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.
Creabilis Pulls In Corporate VC With €15M Series B
Abbott Biotech Ventures is the lead investor in a Series B fundraising for Creabilis to move its psoriasis candidate through Phase II.